Trial Profile
A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine groups C and Y conjugate (Primary)
- Indications Haemophilus infections; Meningococcal group C infections; Meningococcal group Y infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Dec 2016 New trial record